APO Research
Talk to an analyst

APO RESEARCH · REPORT

Solid Preparation Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Solid Preparation Drug Market Outlook and Growth Opportunities 2026

21 December 2025200 pages

Choose your research edition.

Industry ResearchSolid Preparation Drug Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Solid Preparation Drug Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Solid Preparation Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Solid Preparation Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Solid Preparation Drug Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global Solid Preparation Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Solid Preparation Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Solid Preparation Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Solid Preparation Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Solid Preparation Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Solid Preparation Drug market include Takeda, Teva, Sanofi, Johnson & Johnson, Novartis, Merck & Co., Roche, Pfizer and GlaxoSmithKline, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Solid Preparation Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Solid Preparation Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Solid Preparation Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Solid Preparation Drug market.

Solid Preparation Drug Segment by Company

Takeda

Teva

Sanofi

Johnson & Johnson

Novartis

Merck & Co.

Roche

Pfizer

GlaxoSmithKline

Biogen

Bayer

Bristol Myers Squibb

Amgen

AbbVie

AstraZeneca

Gilead Sciences

Eli Lilly & Co.

Boehringer Ingelheim

Astellas

Solid Preparation Drug Segment by Type

Tablet

Capsules

Other

Solid Preparation Drug Segment by Application

Hospital

Retail Pharmacy

Other

Solid Preparation Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Solid Preparation Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Solid Preparation Drug key companies, revenue, market share, and recent developments.

3. To split the Solid Preparation Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Solid Preparation Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Solid Preparation Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Solid Preparation Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Preparation Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Solid Preparation Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Preparation Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Solid Preparation Drug industry.

Chapter 3: Detailed analysis of Solid Preparation Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Solid Preparation Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Solid Preparation Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Solid Preparation Drug Industry Trends Table 2. Solid Preparation Drug Industry Drivers Table 3. Solid Preparation Drug Industry Opportunities and Challenges Table 4. Solid Preparation Drug Industry Restraints Table 5. Global Solid Preparation Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Solid Preparation Drug Revenue Share by Company (2021-2026) Table 7. Global Solid Preparation Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Solid Preparation Drug Key Company Manufacturing Base & Headquarters Table 9. Global Solid Preparation Drug Company, Product Type & Application Table 10. Global Solid Preparation Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Solid Preparation Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tablet Table 15. Significant Companies of Capsules Table 16. Significant Companies of Other Table 17. Global Solid Preparation Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Solid Preparation Drug Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Solid Preparation Drug Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Solid Preparation Drug Sales Value Share by Type (2021-2026) Table 21. Global Solid Preparation Drug Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Retail Pharmacy Table 24. Significant Companies of Other Table 25. Global Solid Preparation Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Solid Preparation Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Solid Preparation Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Solid Preparation Drug Sales Value Share by Application (2021-2026) Table 29. Global Solid Preparation Drug Sales Value Share by Application (2027-2032) Table 30. Global Solid Preparation Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Solid Preparation Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Solid Preparation Drug Sales Value Share by Region (2021-2026) Table 33. Global Solid Preparation Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Solid Preparation Drug Sales Value Share by Region (2027-2032) Table 35. Global Solid Preparation Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Solid Preparation Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Solid Preparation Drug Sales Value Market Share by Country (2021-2026) Table 38. Global Solid Preparation Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Solid Preparation Drug Sales Value Market Share by Country (2027-2032) Table 40. Takeda Company Information Table 41. Takeda Business Overview Table 42. Takeda Solid Preparation Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Takeda Solid Preparation Drug Product Portfolio Table 44. Takeda Recent Development Table 45. Teva Company Information Table 46. Teva Business Overview Table 47. Teva Solid Preparation Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Teva Solid Preparation Drug Product Portfolio Table 49. Teva Recent Development Table 50. Sanofi Company Information Table 51. Sanofi Business Overview Table 52. Sanofi Solid Preparation Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Sanofi Solid Preparation Drug Product Portfolio Table 54. Sanofi Recent Development Table 55. Johnson & Johnson Company Information Table 56. Johnson & Johnson Business Overview Table 57. Johnson & Johnson Solid Preparation Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Johnson & Johnson Solid Preparation Drug Product Portfolio Table 59. Johnson & Johnson Recent Development Table 60. Novartis Company Information Table 61. Novartis Business Overview Table 62. Novartis Solid Preparation Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Novartis Solid Preparation Drug Product Portfolio Table 64. Novartis Recent Development Table 65. Merck & Co. Company Information Table 66. Merck & Co. Business Overview Table 67. Merck & Co. Solid Preparation Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Merck & Co. Solid Preparation Drug Product Portfolio Table 69. Merck & Co. Recent Development Table 70. Roche Company Information Table 71. Roche Business Overview Table 72. Roche Solid Preparation Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Roche Solid Preparation Drug Product Portfolio Table 74. Roche Recent Development Table 75. Pfizer Company Information Table 76. Pfizer Business Overview Table 77. Pfizer Solid Preparation Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Pfizer Solid Preparation Drug Product Portfolio Table 79. Pfizer Recent Development Table 80. GlaxoSmithKline Company Information Table 81. GlaxoSmithKline Business Overview Table 82. GlaxoSmithKline Solid Preparation Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. GlaxoSmithKline Solid Preparation Drug Product Portfolio Table 84. GlaxoSmithKline Recent Development Table 85. Biogen Company Information Table 86. Biogen Business Overview Table 87. Biogen Solid Preparation Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Biogen Solid Preparation Drug Product Portfolio Table 89. Biogen Recent Development Table 90. Bayer Company Information Table 91. Bayer Business Overview Table 92. Bayer Solid Preparation Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Bayer Solid Preparation Drug Product Portfolio Table 94. Bayer Recent Development Table 95. Bristol Myers Squibb Company Information Table 96. Bristol Myers Squibb Business Overview Table 97. Bristol Myers Squibb Solid Preparation Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Bristol Myers Squibb Solid Preparation Drug Product Portfolio Table 99. Bristol Myers Squibb Recent Development Table 100. Amgen Company Information Table 101. Amgen Business Overview Table 102. Amgen Solid Preparation Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Amgen Solid Preparation Drug Product Portfolio Table 104. Amgen Recent Development Table 105. AbbVie Company Information Table 106. AbbVie Business Overview Table 107. AbbVie Solid Preparation Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. AbbVie Solid Preparation Drug Product Portfolio Table 109. AbbVie Recent Development Table 110. AstraZeneca Company Information Table 111. AstraZeneca Business Overview Table 112. AstraZeneca Solid Preparation Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. AstraZeneca Solid Preparation Drug Product Portfolio Table 114. AstraZeneca Recent Development Table 115. Gilead Sciences Company Information Table 116. Gilead Sciences Business Overview Table 117. Gilead Sciences Solid Preparation Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Gilead Sciences Solid Preparation Drug Product Portfolio Table 119. Gilead Sciences Recent Development Table 120. Eli Lilly & Co. Company Information Table 121. Eli Lilly & Co. Business Overview Table 122. Eli Lilly & Co. Solid Preparation Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Eli Lilly & Co. Solid Preparation Drug Product Portfolio Table 124. Eli Lilly & Co. Recent Development Table 125. Boehringer Ingelheim Company Information Table 126. Boehringer Ingelheim Business Overview Table 127. Boehringer Ingelheim Solid Preparation Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. Boehringer Ingelheim Solid Preparation Drug Product Portfolio Table 129. Boehringer Ingelheim Recent Development Table 130. Astellas Company Information Table 131. Astellas Business Overview Table 132. Astellas Solid Preparation Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. Astellas Solid Preparation Drug Product Portfolio Table 134. Astellas Recent Development Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Solid Preparation Drug Product Image Figure 2. Global Solid Preparation Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Solid Preparation Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Solid Preparation Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tablet Image Figure 8. Capsules Image Figure 9. Other Image Figure 10. Global Solid Preparation Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Solid Preparation Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Solid Preparation Drug Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Retail Pharmacy Image Figure 15. Other Image Figure 16. Global Solid Preparation Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Solid Preparation Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Solid Preparation Drug Sales Value Share by Application (2021-2032) Figure 19. Global Solid Preparation Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Solid Preparation Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Solid Preparation Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America Solid Preparation Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Solid Preparation Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Solid Preparation Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Solid Preparation Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Solid Preparation Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Solid Preparation Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America Solid Preparation Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Solid Preparation Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Solid Preparation Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Solid Preparation Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Tablet
  • Capsules
  • Other
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck & Co.
  • Roche
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Bayer
  • Bristol Myers Squibb
  • Amgen
  • AbbVie
  • AstraZeneca
  • Gilead Sciences
  • Eli Lilly & Co.
  • Boehringer Ingelheim
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Solid Preparation Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Solid Preparation Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Solid Preparation Drug Market Dynamics
  1. 2.1 Solid Preparation Drug Industry Trends
  2. 2.2 Solid Preparation Drug Industry Drivers
  3. 2.3 Solid Preparation Drug Industry Opportunities and Challenges
  4. 2.4 Solid Preparation Drug Industry Restraints
3 Solid Preparation Drug Market by Company
  1. 3.1 Global Solid Preparation Drug Company Revenue Ranking in 2025
  2. 3.2 Global Solid Preparation Drug Revenue by Company (2021-2026)
  3. 3.3 Global Solid Preparation Drug Company Ranking (2024-2026)
  4. 3.4 Global Solid Preparation Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Solid Preparation Drug Company Product Type and Application
  6. 3.6 Global Solid Preparation Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Solid Preparation Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Solid Preparation Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Solid Preparation Drug Market by Type
  1. 4.1 Solid Preparation Drug Type Introduction
  2. 4.1.1 Tablet
  3. 4.1.2 Capsules
  4. 4.1.3 Other
  5. 4.2 Global Solid Preparation Drug Sales Value by Type
  6. 4.2.1 Global Solid Preparation Drug Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Solid Preparation Drug Sales Value by Type (2021-2032)
  8. 4.2.3 Global Solid Preparation Drug Sales Value Share by Type (2021-2032)
5 Solid Preparation Drug Market by Application
  1. 5.1 Solid Preparation Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Solid Preparation Drug Sales Value by Application
  6. 5.2.1 Global Solid Preparation Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Solid Preparation Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Solid Preparation Drug Sales Value Share by Application (2021-2032)
6 Solid Preparation Drug Regional Value Analysis
  1. 6.1 Global Solid Preparation Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Solid Preparation Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Solid Preparation Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Solid Preparation Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Solid Preparation Drug Sales Value (2021-2032)
  7. 6.3.2 North America Solid Preparation Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Solid Preparation Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Solid Preparation Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Solid Preparation Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Solid Preparation Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Solid Preparation Drug Sales Value (2021-2032)
  16. 6.6.2 South America Solid Preparation Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Solid Preparation Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Solid Preparation Drug Sales Value Share by Country, 2025 VS 2032
7 Solid Preparation Drug Country-level Value Analysis
  1. 7.1 Global Solid Preparation Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Solid Preparation Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Solid Preparation Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Solid Preparation Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Solid Preparation Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Solid Preparation Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Solid Preparation Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Solid Preparation Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Solid Preparation Drug Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Solid Preparation Drug Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Solid Preparation Drug Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Solid Preparation Drug Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Merck & Co.
  32. 8.6.1 Merck & Co. Company Information
  33. 8.6.2 Merck & Co. Business Overview
  34. 8.6.3 Merck & Co. Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck & Co. Solid Preparation Drug Product Portfolio
  36. 8.6.5 Merck & Co. Recent Developments
  37. 8.7 Roche
  38. 8.7.1 Roche Company Information
  39. 8.7.2 Roche Business Overview
  40. 8.7.3 Roche Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Roche Solid Preparation Drug Product Portfolio
  42. 8.7.5 Roche Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Solid Preparation Drug Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 GlaxoSmithKline
  50. 8.9.1 GlaxoSmithKline Company Information
  51. 8.9.2 GlaxoSmithKline Business Overview
  52. 8.9.3 GlaxoSmithKline Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline Solid Preparation Drug Product Portfolio
  54. 8.9.5 GlaxoSmithKline Recent Developments
  55. 8.10 Biogen
  56. 8.10.1 Biogen Company Information
  57. 8.10.2 Biogen Business Overview
  58. 8.10.3 Biogen Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biogen Solid Preparation Drug Product Portfolio
  60. 8.10.5 Biogen Recent Developments
  61. 8.11 Bayer
  62. 8.11.1 Bayer Company Information
  63. 8.11.2 Bayer Business Overview
  64. 8.11.3 Bayer Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bayer Solid Preparation Drug Product Portfolio
  66. 8.11.5 Bayer Recent Developments
  67. 8.12 Bristol Myers Squibb
  68. 8.12.1 Bristol Myers Squibb Company Information
  69. 8.12.2 Bristol Myers Squibb Business Overview
  70. 8.12.3 Bristol Myers Squibb Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bristol Myers Squibb Solid Preparation Drug Product Portfolio
  72. 8.12.5 Bristol Myers Squibb Recent Developments
  73. 8.13 Amgen
  74. 8.13.1 Amgen Company Information
  75. 8.13.2 Amgen Business Overview
  76. 8.13.3 Amgen Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Amgen Solid Preparation Drug Product Portfolio
  78. 8.13.5 Amgen Recent Developments
  79. 8.14 AbbVie
  80. 8.14.1 AbbVie Company Information
  81. 8.14.2 AbbVie Business Overview
  82. 8.14.3 AbbVie Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AbbVie Solid Preparation Drug Product Portfolio
  84. 8.14.5 AbbVie Recent Developments
  85. 8.15 AstraZeneca
  86. 8.15.1 AstraZeneca Company Information
  87. 8.15.2 AstraZeneca Business Overview
  88. 8.15.3 AstraZeneca Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AstraZeneca Solid Preparation Drug Product Portfolio
  90. 8.15.5 AstraZeneca Recent Developments
  91. 8.16 Gilead Sciences
  92. 8.16.1 Gilead Sciences Company Information
  93. 8.16.2 Gilead Sciences Business Overview
  94. 8.16.3 Gilead Sciences Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Gilead Sciences Solid Preparation Drug Product Portfolio
  96. 8.16.5 Gilead Sciences Recent Developments
  97. 8.17 Eli Lilly & Co.
  98. 8.17.1 Eli Lilly & Co. Company Information
  99. 8.17.2 Eli Lilly & Co. Business Overview
  100. 8.17.3 Eli Lilly & Co. Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Eli Lilly & Co. Solid Preparation Drug Product Portfolio
  102. 8.17.5 Eli Lilly & Co. Recent Developments
  103. 8.18 Boehringer Ingelheim
  104. 8.18.1 Boehringer Ingelheim Company Information
  105. 8.18.2 Boehringer Ingelheim Business Overview
  106. 8.18.3 Boehringer Ingelheim Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Boehringer Ingelheim Solid Preparation Drug Product Portfolio
  108. 8.18.5 Boehringer Ingelheim Recent Developments
  109. 8.19 Astellas
  110. 8.19.1 Astellas Company Information
  111. 8.19.2 Astellas Business Overview
  112. 8.19.3 Astellas Solid Preparation Drug Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Astellas Solid Preparation Drug Product Portfolio
  114. 8.19.5 Astellas Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst